Clinical trials
catalyst calendar across sponsors →Studies where SABS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 with posted results
Held by 6 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, +1 more) · FINRA short interest 8.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs)Randomized · Double-masked · Other | Phase 2 | Recruiting | Drug: High Dose SAB-142, Low Dose SAB-142 · Other: Placebo | Type 1 Diabetes | 159 | Nov 2027 | ≤ 468 d | 2026-07-10 |
| A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With PlaceboNCT06435936Occurrence of solicited local and systemic adverse events (AEs) through Day 29.Randomized · Double-masked · Basic science | Phase 1 | Active, not recruiting | Drug: Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo | PHA1A | 28 | 2025-02-01 | — | 2024-09-19 |
| Study of SAB-176 in Healthy Adult ParticipantsNCT04850898results2025-01-22To Evaluate Viral Load by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) of SAB-176 When Compared to PlaceboRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: SAB-176 · Other: Placebo | Influenza A H1N1 | 62 | 2021-10-08actual | — | 2025-01-22 |
| Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy ParticipantsNCT04471038results2025-01-06Number of Participants Having Adverse EventsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: SAB-176 · Other: Normal Saline | Influenza Type A, Influenza Type B, Influenza | 27 | 2021-04-19actual | — | 2025-01-06 |
| Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19NCT04469179Number of Participants Having Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Unknown status | Biological: SAB-185 · Other: Normal Saline | COVID-19, SARS-CoV2 | 21 | 2021-02-25actual | — | 2021-10-26 |
| Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy ParticipantsNCT04468958Number of Participants Having Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: SAB-185 · Other: Normal saline | COVID-19, SARS-CoV2 | 28 | 2020-12-23actual | — | 2022-07-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19